Results of a Phase 1b/2 Study of ADG126 (a Masked Anti-CTLA-4 SAFEbody®) in Combination with Pembrolizumab (Pembro) in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) ADG126 | ASCO-GI 2024
